Catherine Bakari, Celine I Mandara, Rashid A Madebe, Misago D Seth, Billy Ngasala, Erasmus Kamugisha, Maimuna Ahmed, Filbert Francis, Samwel Bushukatale, Mercy Chiduo, Twilumba Makene, Abdunoor M Kabanywanyi, Muhidin K Mahende, Reginald A Kavishe, Florida Muro, Sigsbert Mkude, Renata Mandike, Fabrizio Molteni, Frank Chacky, Dunstan R Bishanga, Ritha J A Njau, Marian Warsame, Bilali Kabula, Ssanyu S Nyinondi, Naomi W Lucchi, Eldin Talundzic, Meera Venkatesan, Leah F Moriarty, Naomi Serbantez, Chonge Kitojo, Erik J Reaves, Eric S Halsey, Ally Mohamed, Venkatachalam Udhayakumar, Deus S Ishengoma
BACKGROUND: Therapeutic efficacy studies (TESs) and detection of molecular markers of drug resistance are recommended by the World Health Organization (WHO) to monitor the efficacy of artemisinin-based combination therapy (ACT). This study assessed the trends of molecular markers of artemisinin resistance and/or reduced susceptibility to lumefantrine using samples collected in TES conducted in Mainland Tanzania from 2016 to 2021. METHODS: A total of 2,015 samples were collected during TES of artemether-lumefantrine at eight sentinel sites (in Kigoma, Mbeya, Morogoro, Mtwara, Mwanza, Pwani, Tabora, and Tanga regions) between 2016 and 2021...
March 9, 2024: Malaria Journal